• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Introduction to 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine (CAS No: 1201935-88-7)

1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine, identified by its CAS number 1201935-88-7, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This heterocyclic amine features a pyrazole core substituted with a difluoromethyl group at the 1-position and a methyl group at the 3-position, along with an amine functional group at the 4-position. The unique structural attributes of this compound make it a promising candidate for further exploration in drug discovery and development.

The pyrazole scaffold is a well-documented motif in medicinal chemistry, known for its versatility and biological activity. Pyrazoles exhibit a broad spectrum of pharmacological properties, including antiviral, anti-inflammatory, and anticancer effects. The introduction of fluorine atoms into the molecular structure, particularly as a difluoromethyl group, is a common strategy to enhance metabolic stability, binding affinity, and overall pharmacological efficacy. In the case of 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine, the presence of these substituents may contribute to its potential as an intermediate or lead compound in the synthesis of novel therapeutic agents.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the biological activity of compounds like 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine with greater accuracy. Studies have shown that fluorinated pyrazoles can interact with biological targets in unique ways, often leading to improved drug-like properties. For instance, the electron-withdrawing nature of fluorine atoms can modulate the electronic distribution within the molecule, influencing its binding interactions with enzymes and receptors. This has opened up new avenues for designing more effective and selective drugs.

Moreover, the methyl group at the 3-position of the pyrazole ring may play a crucial role in determining the compound's solubility, bioavailability, and metabolic pathways. The combination of these structural elements suggests that 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine could exhibit distinct pharmacokinetic profiles compared to other pyrazole derivatives. This makes it an intriguing subject for further investigation into its potential applications in treating various diseases.

In the realm of drug discovery, intermediates like 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine are often used as building blocks for more complex molecules. The amine functional group at the 4-position provides a reactive site for further chemical modifications, allowing chemists to tailor the compound's properties for specific therapeutic needs. Researchers have been exploring various synthetic routes to incorporate this scaffold into larger drug molecules, leveraging its inherent biological potential.

One area where 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine shows promise is in the development of antiviral agents. The pyrazole core has been identified as a key structural component in several antiviral drugs, highlighting its importance in combating viral infections. The fluorinated derivatives of pyrazole are particularly interesting due to their enhanced stability and bioavailability. Preliminary studies have suggested that compounds with similar structures may inhibit viral proteases or integrases, thereby disrupting viral replication cycles.

Another emerging application of this compound is in oncology research. Cancer therapies often require molecules that can selectively target malignant cells while minimizing side effects on healthy tissues. The unique electronic properties of 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine make it a candidate for developing kinase inhibitors or other targeted therapies. By modulating specific signaling pathways involved in cancer progression, this compound could potentially offer a new approach to treating various types of cancer.

The synthesis of 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advanced synthetic techniques, such as cross-coupling reactions and transition metal catalysis, have been employed to introduce the desired substituents onto the pyrazole backbone. These methods not only enhance efficiency but also allow for greater control over the stereochemistry of the final product.

Quality control and analytical characterization are critical steps in evaluating 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine before it can be used in pharmaceutical applications. Techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and high-performance liquid chromatography (HPLC) are routinely employed to confirm its identity and purity. These analytical methods provide detailed insights into the molecular structure and help ensure that the compound meets stringent regulatory standards.

The future prospects for 1-(Difluoromethyl)-3-methyl-1H-pyrazol-4-amine are vast, given its potential as both an intermediate and an active pharmaceutical ingredient (API). Ongoing research aims to elucidate its mechanism of action and explore new therapeutic applications. Collaborative efforts between academic institutions and pharmaceutical companies are likely to drive innovation in this area, leading to novel treatments for various diseases.

In conclusion, 1-(Difluoromethyl)-3-methyl-1H-pyrazol -4 -amine (CAS No: 1201935 -88 -7) represents a significant advancement in medicinal chemistry due to its unique structural features and promising biological activities. Its potential applications in antiviral and anticancer therapies make it a valuable compound for further research and development. As our understanding of molecular interactions continues to grow, this compound will undoubtedly play an important role in shaping future therapeutic strategies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)